SYN-AKE

SYN-AKE is a patented synthetic tripeptide that mimics the paralytic action of Waglerin-1, a peptide component of the venom of the Temple Pit Viper (Tropidolaemus wagleri). Developed by DSM (formerly Pentapharm), it works by transiently relaxing facial muscles responsible for expression wrinkles. Unlike Argireline-class peptides that target the SNARE complex, SYN-AKE acts directly at the nicotinic acetylcholine receptor.

SYN-AKE acts as a competitive antagonist at the muscular nicotinic acetylcholine receptor (mnAChR). In normal neuromuscular transmission, acetylcholine binds mnAChR to trigger muscle fiber contraction. SYN-AKE competes for this receptor binding site, reducing the efficiency of signal transduction without blocking it completely. This partial inhibition attenuates facial muscle contractility in a reversible and dose-dependent manner, reducing the mechanical stress that deepens expression lines. In vitro studies showed up to 80% reduction in muscle contraction signaling at effective concentrations.

In vitro receptor-binding studies show up to 80% attenuation of mnAChR-driven muscle contraction. A 28-day clinical trial reported significant reduction in wrinkle depth and skin smoothness improvements observable by digital imaging. Effect is fully reversible and non-paralytic. All published evidence is from the manufacturer or cosmetic ingredient suppliers; no independent RCTs as of 2026.

Peptides commonly paired with SYN-AKE for synergistic effects.